Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors.

PMID: 31053787
Journal: EUROPEAN JOURNAL OF HUMAN GENETICS
Year: 2019
Reference: Eur J Hum Genet. 2019 Dec;27(12):1774-1782. doi: 10.1038/s41431-019-0415-4. Epub 2019 May 3.
Impact factor:
Publication type: Review in international publication
Authors: Serra-Juhe, Clara; Tizzano, Eduardo F et al.
DOI: 10.1038/s41431-019-0415-4

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

PMID: 31283872
Journal: Transplant Infectious Disease
Year: 2019
Reference: Transpl Infect Dis. 2019 Oct;21(5):e13141. doi: 10.1111/tid.13141. Epub 2019 Jul 22.
Impact factor: 2.112
Publication type: Paper in international publication
Authors: Luong, Me-Linh, Seidel, Danila, Grossi, Paolo, Husain, Shahid, Picard, Clement, Lass-Florl, Cornelia, Manuel, Oriol, Le Pavec, Jerome, Lortholary, Olivier, Nagel, Claudia et al.
DOI: 10.1111/tid.13141

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

PMID: 31283872
Journal: Transplant Infectious Disease
Year: 2019
Reference: Transpl Infect Dis. 2019 Oct;21(5):e13141. doi: 10.1111/tid.13141. Epub 2019 Jul 22.
Impact factor:
Publication type: Paper in international publication
Authors: Aslam, Saima; Baddley, John; Benden, Christian; Bervar, Jean-Francois; Bhorade, Sangeeta; Blanchard, Elodie; Boussaud, Veronique; Brill, Anne Kathrin; Brugiere, Olivier; Budem, Marie et al.
DOI: 10.1111/tid.13141

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

PMID: 31333640
Journal: Frontiers in Immunology
Year: 2019
Reference: Front Immunol. 2019 Jul 3;10:1344. doi: 10.3389/fimmu.2019.01344. eCollection 2019.
Impact factor: 4.716
Publication type: Review in international publication
Authors: Esposito, Susanna, Stefanelli, Paola, Fry, Norman K, Fedele, Giorgio, He, Qiushui, Paterson, Pauline, Tan, Tina, Knuf, Markus, Rodrigo, Carlos, Weil Olivier, Catherine et al.
DOI: 10.3389/fimmu.2019.01344

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

PMID: 31333640
Journal: Frontiers in Immunology
Year: 2019
Reference: Front Immunol. 2019 Jul 3;10:1344. doi: 10.3389/fimmu.2019.01344. eCollection 2019.
Impact factor:
Publication type: Review in international publication
Authors: Edwards, Kathryn; Esposito, Susanna; Fedele, Giorgio; Flanagan, Katie L; Fry, Norman K; He, Qiushui; Hung, Ivan; Knuf, Markus; Lutsar, Iria; O'Ryan, Miguel et al.
DOI: 10.3389/fimmu.2019.01344

PET or MRI to improve response evaluation in clinical trials?

PMID: 31486372
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Aug;20(8):1060-1062. doi: 10.1016/S1470-2045(19)30465-6. Epub 2019 Jul 29.
Impact factor: 35.386
Publication type: Editorail in international publication
Authors: Deroose, Christophe M, Gheysens, Olivier, Perez-Lopez, Raquel et al.
DOI: 10.1016/S1470-2045(19)30465-6

PET or MRI to improve response evaluation in clinical trials?

PMID: 31486372
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Aug;20(8):1060-1062. doi: 10.1016/S1470-2045(19)30465-6. Epub 2019 Jul 29.
Impact factor:
Publication type: Editorail in international publication
Authors: Deroose, Christophe M; Gheysens, Olivier; Perez-Lopez, Raquel et al.
DOI: 10.1016/S1470-2045(19)30465-6

PET Scan: Nuclear Medicine Imaging in Myositis.

PMID: 31754890
Journal: Current Rheumatology Reports
Year: 2019
Reference: Curr Rheumatol Rep. 2019 Nov 21;21(11):64. doi: 10.1007/s11926-019-0864-3.
Impact factor: 3.645
Publication type: Review in international publication
Authors: Selva-O'Callaghan, Albert, Gil-Vila, Albert, Simo-Perdigo, Marc, Trallero-Araguas, Ernesto, Alvarado-Cardenas, Marcelo, Pinal-Fernandez, Iago et al.
DOI: 10.1007/s11926-019-0864-3

PET Scan: Nuclear Medicine Imaging in Myositis.

PMID: 31754890
Journal: Current Rheumatology Reports
Year: 2019
Reference: Curr Rheumatol Rep. 2019 Nov 21;21(11):64. doi: 10.1007/s11926-019-0864-3.
Impact factor:
Publication type: Review in international publication
Authors: Alvarado-Cardenas, Marcelo; Gil-Vila, Albert; Pinal-Fernandez, Iago; Selva-O'Callaghan, Albert; Simo-Perdigo, Marc; Trallero-Araguas, Ernesto et al.
DOI: 10.1007/s11926-019-0864-3

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

PMID: 30865352
Journal: Transplant Infectious Disease
Year: 2019
Reference: Transpl Infect Dis. 2019 Jun;21(3):e13072. doi: 10.1111/tid.13072. Epub 2019 Mar 27.
Impact factor: 2.112
Publication type: Review in international publication
Authors: Los-Arcos, Ibai, Royuela, Meritxell, Martin-Gomez, Maria Teresa, Alastruey-Izquierdo, Ana, Sellares, Joana, Perello, Manel, Castells, Lluis, Dopazo, Cristina, Gavalda, Joan, Len, Oscar et al.
DOI: 10.1111/tid.13072

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

PMID: 30865352
Journal: Transplant Infectious Disease
Year: 2019
Reference: Transpl Infect Dis. 2019 Jun;21(3):e13072. doi: 10.1111/tid.13072. Epub 2019 Mar 27.
Impact factor:
Publication type: Review in international publication
Authors: Alastruey-Izquierdo, Ana; Castells, Lluis; Dopazo, Cristina; Gavalda, Joan; Len, Oscar; Los-Arcos, Ibai; Martin-Gomez, Maria Teresa; Perello, Manel; Royuela, Meritxell; Sellares, Joana et al.
DOI: 10.1111/tid.13072

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

PMID: 31183514
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2019
Reference: Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.
Impact factor: 3.008
Publication type: Paper in international publication
Authors: Wang, Bei, Kirschbrown, Whitney P, Hoff, Paulo M, Shah, Manish A, Shen, Lin, Kang, Yoon-Koo, Alsina, Maria, Girish, Sandhya, Garg, Amit, Ohtsu, Atsushi et al.
DOI: 10.1007/s00280-019-03871-w

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

PMID: 31183514
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2019
Reference: Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10.
Impact factor:
Publication type: Paper in international publication
Authors: Alsina, Maria; Garg, Amit; Girish, Sandhya; Hoff, Paulo M; Kang, Yoon-Koo; Kirschbrown, Whitney P; Nijem, Ihsan; Ohtsu, Atsushi; Shah, Manish A; Shen, Lin et al.
DOI: 10.1007/s00280-019-03871-w

Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes.

PMID: 30633087
Journal: THERAPEUTIC DRUG MONITORING
Year: 2019
Reference: Ther Drug Monit. 2019 Jun;41(3):376-382. doi: 10.1097/FTD.0000000000000595.
Impact factor:
Publication type: Paper in international publication
Authors: Fortun, Jesus; Grau, Santiago; Liano, Fernando; Luque, Sonia; Roberts, Jason A; Tenorio-Canamas, Teresa et al.
DOI: 10.1097/FTD.0000000000000595

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

PMID: 29954928
Journal: HAEMATOLOGICA
Year: 2019
Reference: Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.
Impact factor: 7.57
Publication type: Paper in international publication
Authors: Guerrero-Hernandez, Martina, Rodriguez, Vanina, Soldini, Davide, Valera, Alexandra, Moros, Alexandra, Climent, Fina, Gonzalez-Barca, Eva, Mercadal, Santiago, Arenillas, Leonor, Calvo, Xavier et al.
DOI: 10.3324/haematol.2017.180505

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

PMID: 29954928
Journal: HAEMATOLOGICA
Year: 2019
Reference: Haematologica. 2019 Apr;104(4):778-788. doi: 10.3324/haematol.2017.180505. Epub 2018 Jun 28.
Impact factor:
Publication type: Paper in international publication
Authors: Arenillas, Leonor; Borrell, Jose Ignacio; Bueno, Clara; Calvo, Xavier; Campo, Elias; Cardesa-Salzmann, Teresa; Casanova, Isolda; Climent, Fina; Clot, Guillem; Colomer, Dolors et al.
DOI: 10.3324/haematol.2017.180505

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

PMID: 31581671
Journal: Cancers
Year: 2019
Reference: Cancers (Basel). 2019 Oct 2;11(10). pii: cancers11101483. doi: 10.3390/cancers11101483.
Impact factor: 6.162
Publication type: Review in international publication
Authors: Reyes-Garau, Diana, Ribeiro, Marcelo L, Roue, Gael et al.
DOI: 10.3390/cancers11101483

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

PMID: 31581671
Journal: Cancers
Year: 2019
Reference: Cancers (Basel). 2019 Oct 2;11(10). pii: cancers11101483. doi: 10.3390/cancers11101483.
Impact factor:
Publication type: Review in international publication
Authors: Reyes-Garau, Diana; Ribeiro, Marcelo L; Roue, Gael et al.
DOI: 10.3390/cancers11101483

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

PMID: 31481511
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Cleverly, Ann, Lahn, Michael M, Janssen, Jan, Zhao, Yumin, Chiang, Alan, Giagounidis, Aristoteles, Guba, Susan C, Sridharan, Ashwin, Gueorguieva, Ivelina, Girvan, Alicia et al.
DOI: 10.1158/1078-0432.CCR-19-1338

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

PMID: 31481511
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Dec 1;25(23):6976-6985. doi: 10.1158/1078-0432.CCR-19-1338. Epub 2019 Sep 3.
Impact factor:
Publication type: Paper in international publication
Authors: Bhagat, Tushar D; Chiang, Alan; Cleverly, Ann; da Silva Ferreira, Mariana; Giagounidis, Aristoteles; Girvan, Alicia; Guba, Susan C; Gueorguieva, Ivelina; Janssen, Jan; Komrokji, Rami S et al.
DOI: 10.1158/1078-0432.CCR-19-1338

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

PMID: 32085233
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Macarulla, T, Javle, M, Borbath, I, Clarke, S, Hitre, E, Louvet, C, Valle, J, Weiss, K, Berman, C, Howland, M et al.
DOI: 10.1093/annonc/mdz155.224

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

PMID: 32085233
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4.
Impact factor:
Publication type: Letter or abstract
Authors: Abou-Alfa, G; Berman, C; Borbath, I; Cho, T; Clarke, S; Hitre, E; Howland, M; Javle, M; Louvet, C; Macarulla, T et al.
DOI: 10.1093/annonc/mdz155.224

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

PMID: 30889492
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: Hollebecque, Antoine, Calvo, Aitana, Dahan, Laetitia, Cervantes, Andres, Leger, Catherine, Amellal, Nadia, Fougeray, Ronan, Tabernero, Josep, Andre, Thierry, Argiles, Guillem et al.
DOI: 10.1016/j.ejca.2019.01.101

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

PMID: 30889492
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.
Impact factor:
Publication type: Paper in international publication
Authors: Amellal, Nadia; Andre, Thierry; Argiles, Guillem; Calvo, Aitana; Cervantes, Andres; Dahan, Laetitia; Fougeray, Ronan; Hollebecque, Antoine; Leger, Catherine; Tabernero, Josep et al.
DOI: 10.1016/j.ejca.2019.01.101

Publications

Publications searcher

Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors.

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology.

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.

PET or MRI to improve response evaluation in clinical trials?

PET or MRI to improve response evaluation in clinical trials?

PET Scan: Nuclear Medicine Imaging in Myositis.

PET Scan: Nuclear Medicine Imaging in Myositis.

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

Phaeohyphomycosis caused by Medicopsis romeroi in solid organ transplant recipients: report of two cases and comprehensive review of the literature.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

Patronage:

Collaborating:

Accreditations: